| abstract |
An antibody binding to human CCR5 comprising a variable heavy chain and a variable light chain, characterized in that the variable heavy chain comprises CDR sequences CDRl, CDR2 and CDR3 and CDRl being selected from the group consisting of SEQ ID NOs: 9, 10, 11, 12, CDR2 being selected from the group consisting of SEQ ID NOs: 13, 14, 15, CDR3 being selected from the group consisting of SEQ ID NOs: 16, 17, wherein said CDRs are selected independently of each other, or is a chimeric, humanized variant or a fragment of said antibody, has advantageous properties for the treatment of immunosuppressive diseases. |